CA-074: Selective Cathepsin B Inhibitor for Cancer Metastasis and Neurotoxicity Research

Executive Summary: CA-074 is a potent, selective inhibitor of cathepsin B (Ki = 2–5 nM), showing >10,000-fold selectivity over cathepsins H and L (Ki = 40–200 μM) [APExBIO product datasheet]. It effectively blocks cathepsin B-dependent proteolytic events involved in tumor metastasis, neurotoxicity, and immune regulation (Liu et al., 2023). In preclinical models, CA-074 reduces bone metastasis in breast cancer and suppresses Abeta42-induced neurotoxicity [CA-074.com]. The compound is highly soluble in DMSO (>19.17 mg/mL), ethanol (>31.3 mg/mL), and water (>5.91 mg/mL with ultrasonication), facilitating diverse laboratory workflows. At 10 mM, CA-074 shows negligible cytotoxicity in cell culture, supporting its use in both in vitro and in vivo applications [DOI].

Biological Rationale

Cathepsin B is a lysosomal cysteine protease involved in protein degradation, extracellular matrix remodeling, and cell death regulation (Liu et al., 2023). Overexpression and mislocalization of cathepsin B are linked to tumor invasion, metastasis, and neurodegenerative processes. During necroptosis, lysosomal membrane permeabilization (LMP) occurs, triggering the cytosolic release of cathepsin B, which then cleaves essential proteins and amplifies cell death signals. Inhibition of cathepsin B has been shown to protect cells from LMP-induced necroptosis (Fig. 1–2). Cathepsin B also regulates immune responses, modulating helper T cell differentiation and antibody class switching [APExBIO].

Mechanism of Action of CA-074, Cathepsin B Inhibitor

CA-074 is a peptidyl epoxide that forms a covalent bond with the active site cysteine of cathepsin B, irreversibly inhibiting its proteolytic activity (Liu et al., 2023). With a Ki of 2–5 nM, CA-074 demonstrates high affinity and selectivity for cathepsin B over other cathepsins, minimizing off-target effects [Product Page]. By blocking cathepsin B, CA-074 interrupts proteolytic cascades involved in:

• Degradation of extracellular matrix components that facilitate tumor cell invasion
• Cleavage of proteins critical for cell survival during necroptosis
• Processing of immune modulators that influence Th-1/Th-2 balance

These mechanisms underlie CA-074's efficacy in reducing cancer metastasis, abrogating neurotoxicity, and shifting immune responses.

Evidence & Benchmarks

• CA-074 inhibits cathepsin B activity in vitro with a Ki of 2–5 nM, while showing >10,000-fold selectivity over cathepsins H and L (Ki = 40–200 μM) (APExBIO).
• In a 4T1.2 breast cancer mouse model, CA-074 (50 mg/kg, intraperitoneal) significantly reduced bone metastasis without altering primary tumor growth (APExBIO).
• CA-074 blocks cathepsin B-mediated cell death in necroptosis by preventing LMP-induced release of lysosomal contents (Liu et al., 2023).
• In microglial cell assays, CA-074 suppresses Abeta42-induced neurotoxicity, indicating utility in neurodegeneration models (CA-074.com).
• CA-074 modulates immune response by shifting helper T cell activity from Th-2 to Th-1, reducing IgE and IgG1 production in vivo (CA-074.com).
• In cell culture, CA-074 shows negligible cytotoxicity at 10 mM (APExBIO).

This article extends insights from "CA-074: Advancing Cathepsin B Inhibition in Necroptosis" by providing updated quantitative selectivity data and a comprehensive workflow integration guide for translational research. For benchmark comparisons in immune modulation, see "CA-074: Selective Cathepsin B Inhibitor for Cancer Metastasis", which this article expands by detailing cytotoxicity thresholds and solubility profiles relevant to cell-based assays. Additionally, "Unlocking Cathepsin B Inhibition for Targeted Cancer Studies" is clarified here with updated in vivo efficacy data and mechanistic evidence from MLKL-LMP necroptosis studies.

Applications, Limits & Misconceptions

CA-074 is validated for use in cancer metastasis models, neurotoxicity assays, and studies of immune response modulation. Its high selectivity and solubility make it suitable for in vitro and in vivo workflows. However, users should be aware of boundaries in target specificity and appropriate experimental controls.

Common Pitfalls or Misconceptions

• Non-selectivity for other cathepsins: While highly selective for cathepsin B, CA-074 is ineffective against cathepsins H and L at standard concentrations (Ki > 40 μM).
• Irreversible inhibition: CA-074 forms a covalent bond, making its inhibition irreversible; this may confound time-course experiments if replenishment is not considered.
• Limited effect on primary tumor growth: In vivo studies show CA-074 reduces metastasis but does not impact primary tumor size (APExBIO).
• Storage and stability: CA-074 solutions should be freshly prepared for each experiment and stored at -20°C; degradation may occur with repeated freeze-thaw cycles.
• Solubility constraints in aqueous buffer: For maximal solubility in water, ultrasonic assistance is required; otherwise, DMSO or ethanol are preferred solvents.

Workflow Integration & Parameters

CA-074 (APExBIO SKU A1926) is supplied as a lyophilized powder with a molecular weight of 383.44 g/mol. For in vitro use, stock solutions can be prepared in DMSO (>19.17 mg/mL), ethanol (>31.3 mg/mL), or water (>5.91 mg/mL with ultrasonication). Solutions should be aliquoted and stored at -20°C for short-term use. In cell-based assays, CA-074 is non-cytotoxic at concentrations up to 10 mM. In vivo, a dosing regimen of 50 mg/kg via intraperitoneal injection in mice has demonstrated efficacy in metastasis inhibition. For optimal results:

• Validate target engagement with cathepsin B activity assays.
• Include vehicle and positive control arms in experimental design.
• Monitor for off-target effects by confirming lack of inhibition of cathepsins H and L.

For advanced protocols and assay optimization, see "Optimizing Cell Death and Metastasis Assays with CA-074", which this article updates with recent stability and cytotoxicity data.

Conclusion & Outlook

CA-074, Cathepsin B inhibitor, provides a robust platform for dissecting the role of cathepsin B in cancer metastasis, necroptosis, and immune modulation. Its exceptional selectivity and low cytotoxicity profile, as established by APExBIO and independent peer-reviewed research, make it a gold standard tool for mechanistic and translational studies. Future research may expand its relevance to additional disease models where cathepsin B-driven proteolysis is implicated. For comprehensive protocol details and ordering, visit the official CA-074 product page.